Recurrence-free and 5-year survival following robotic-assisted surgical staging for endometrial carcinoma
Recurrence-free and 5-year survival following robotic-assisted surgical staging for endometrial carcinoma
复制标题
DOI：
10.1016/j.ygyno.2012.12.020
复制
发表时间：
2013-04-01
影响因子：
4.7
通讯作者：
Boggess, John F.
中科院分区：
文献类型：
--
作者：
Kilgore, Joshua E.;Jackson, Amanda L.;Boggess, John F.
客观的。本研究的目的是报告使用机器人辅助腹腔镜手术进行分期的子宫内膜腺癌女性的无复发和总生存率。方法。对 2005 年至 2010 年在北卡罗来纳大学医院通过机器人辅助腹腔镜手术进行分期的所有连续子宫内膜腺癌患者进行了回顾性图表审查。分析了人口统计数据、5 年生存率和无复发间隔。使用 SAS 软件使用卡方、t 检验和 Kaplan-Meier 曲线进行统计分析。研究结果与美国国家癌症研究所流行病学监测和最终结果数据库中的子宫内膜癌统计数据进行了比较。结果。共有 499 名患者被确定并纳入该研究。机器人辅助手术分期后，IA 期无复发间隔为 85.2%，IB 期为 80.2%，II 期为 69.8%，III 期为 69%。研究中所有患者的预计 5 年生存率为 88.7%。近82%的病例为子宫内膜样腺癌，其中乳头状浆液性、透明细胞或混合组织学占17.4%。中位随访时间为 23 个月，范围为 0 至 80 个月。在 IA、IB、II 和 III 期患者中，预计总生存率分别为 94.2%、85.9%、77.4% 和 68.6%。结论。这项研究的结果表明，机器人辅助子宫内膜癌手术分期不会对复发率或生存率产生不利影响。这些发现进一步证明，与剖腹手术或传统腹腔镜手术相比，机器人辅助腹腔镜手术分期与较差的结果无关。 (C) 2012 Elsevier Inc. 保留所有权利。
Objective. The aim of this study is to report recurrence-free and overall survival for women with endometrial adenocarcinoma who were surgically staged using robotic-assisted laparoscopy.Methods. A retrospective chart review was performed for all consecutive endometrial adenocarcinoma patients surgically staged with robotic-assisted laparoscopy at the University of North Carolina Hospital from 2005 to 2010. Demographic data, 5-year survival, and recurrence-free intervals were analyzed. Statistical analysis using Chi-square, t-test, and Kaplan-Meier curves were performed with SAS software. Study results were compared to endometrial cancer statistics from the Surveillance Epidemiology and End Results database from the National Cancer Institute.Results. A total of 499 patients were identified and included in the study. Recurrence-free intervals after robotic-assisted surgical staging were 85.2% for stage IA, 80.2% for stage IB, 69.8% for stage II, and 69% for stage III. Projected 5-year survival was 88.7% for all patients included in the study. Nearly 82% of cases were endometrioid adenocarcinoma, with papillary serous, clear cell or mixed histology comprising 17.4% of cases. Median follow up time was 23 months, with a range of 0 to 80 months. Among stage IA, IB, II, and III patients, projected overall survival was 94.2%, 85.9%, 77.4%, and 68.6%, respectively.Conclusions. The results from this study demonstrate that robotic-assisted surgical staging for endometrial cancer does not adversely affect rates of recurrence or survival. These findings provide further evidence that robotic-assisted laparoscopic surgical staging is not associated with inferior results when compared to laparotomy or traditional laparoscopy. (C) 2012 Elsevier Inc. All rights reserved.